American journal of clinical and experimental urology最新文献

{"title":"Renal cell carcinoma with unusual morphological features: the clinical utility of next-generation sequencing in distinguishing renal cell tumors.","authors":"Jennifer Lee, Xiuping Yu, Yunshin A Yeh","doi":"10.62347/EGWC8899","DOIUrl":"10.62347/EGWC8899","url":null,"abstract":"<p><strong>Objectives: </strong>Clear cell and papillary renal cell carcinomas (RCC) are the two most common RCC subtypes, accounting for approximately 70% and 15% of kidney cancers, respectively. Clear cell RCC is commonly associated with <i>VHL</i> alterations, while papillary RCC typically exhibits chromosomal abnormalities such as +7, +17, and -Y. Furthermore, clear cell RCCs are less likely to exhibit <i>PBRM1</i> and <i>SETD2</i> alterations. This study aims to improve the accuracy of RCC diagnosis by investigating molecular alterations in RCC cases with clear cells, papillary structures, and other atypical histological features.</p><p><strong>Methods: </strong>Nine RCC cases were retrospectively selected and analyzed using histologic slides and immunohistochemical staining for CAIX, RCC, CD10, CK7, P504S, Vimentin, and EMA. Next-generation sequencing was performed on all cases to identify genetic mutations, and cytogenetic analysis was conducted on one case.</p><p><strong>Results: </strong>The cohort consisted of nine male patients aged 49 to 68 years (mean 61.4). Surgical specimens included six radical and three partial nephrectomies; seven tumors were located in the left kidney and two in the right. Tumor sizes ranged from 0.8 to 15.2 cm. Immunohistochemical analysis revealed positive staining for RCC (6/9), CAIX (3/4), CD10 (6/6), and CK7 (5/9). In six clear cell RCCs, next-generation sequencing identified <i>VHL</i> mutations in four tumors, <i>PBRM1</i> alterations in three, and <i>SETD2</i> mutations in one. Five tumors with papillary fronds, sarcomatous components, or unclassified features harboring <i>VHL</i>, <i>PBRM1</i>, and/or <i>SETD2</i> mutations were reclassified as clear cell RCC. One clear cell RCC with leiomyomatous stroma showed <i>mTOR</i> mutations. A case of clear cell papillary renal cell neoplasm showed no reportable gene mutations. The role of a <i>FANCA</i> mutation in one papillary RCC remains uncertain. Cytogenetic analysis of one case (Case #5) revealed 50, X, -Y, +3, +7, +16, +17, +20, consistent with papillary RCC.</p><p><strong>Conclusions: </strong>Next-generation sequencing is a useful method for categorizing RCCs with clear cells, papillary features, and unusual histology. Additionally, <i>VHL</i> mutations could be a promising target for personalized treatment in clear cell RCCs and their histologic variants.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"284-293"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced detection of clinically significant prostate cancer in targeted and non-targeted regions using BiopSee^® MRI/ultrasound fusion biopsy.","authors":"Ken Nakahara, Daisuke Obinata, Sho Hashimoto, Kazuki Ohashi, Yuki Inagaki, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi, Satoru Takahashi","doi":"10.62347/QODA6396","DOIUrl":"10.62347/QODA6396","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the cancer detection profile of magnetic resonance imaging/transrectal ultrasound fusion-guided biopsies (fusion biopsy) using the BiopSee^® system in patients assessed with the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1, focusing on clinically significant prostate cancer (csPCa) detection in regions of interest (ROI) and non-ROI areas.</p><p><strong>Methods: </strong>We retrospectively analyzed 59 patients who underwent fusion biopsy between February and November 2024. Detection rates of csPCa (grade group ≥ 2) were compared between the ROI and non-ROI regions, and clinical and biopsy characteristics were compared between patients with and without csPCa. Univariate logistic regression analysis was performed to identify predictors of csPCa.</p><p><strong>Results: </strong>The median patient age was 74 years, with a median prostate-specific antigen (PSA) level of 8.93 ng/mL. The csPCa detection rate was significantly higher in the ROI than in the non-ROI regions (61% vs. 44%, P = 0.012). Across the cohort, PI-RADS 4 and 5 lesions were more common than PI-RADS 3 lesions. A higher PI-RADS score (4 or 5) was identified as a significant predictor of csPCa detection (odds ratio 5.14, P = 0.034), whereas age, PSA, number of ROIs, and biopsy core numbers were not significant predictors.</p><p><strong>Conclusions: </strong>Fusion biopsy using the BiopSee^® system achieved a high csPCa detection rate in targeted ROIs, especially for PI-RADS 4 and 5 lesions, while also highlighting the importance of combining systematic biopsy with targeted approaches because of the substantial proportion of csPCa detected in non-ROI regions.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"265-271"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of commonly used medications on the detection of clinically significant prostate cancer in the targeted biopsy era.","authors":"Krista N Brackman, Marcelo P Bigarella, Arighno Das, Diana Garcia, Glenn O Allen, David Jarrard","doi":"10.62347/IWZF5622","DOIUrl":"10.62347/IWZF5622","url":null,"abstract":"<p><strong>Objectives: </strong>To compare prostate cancer rates in magnetic resonance imaging (MRI)-detected lesions for patients who are chronically taking beta-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressors.</p><p><strong>Methods: </strong>This cohort consisted of 897 Prostate Imaging Reporting & Data System (PI-RADS)v2 3-5 lesions from 590 MRI-targeted fusion prostate biopsies (UroNav). Baseline characteristics and clinicopathological data were collected. A matching cohort was analyzed, and multivariate analysis was completed for each medication group. Matching analysis accounted for age, prostate-specific antigen (PSA), and PI-RADS score. Multivariate analysis additionally considered lesion size.</p><p><strong>Results: </strong>Of the 897 lesions, 261/897 (29%) of lesions were identified as PI-RADS 3, 373/897 (42%) were PI-RADS 4, and 263/897 (29%) were PI-RADS 5. In the patient cohort, 16% were taking a beta-blocker, 3.9% were taking an NSAID, and 5.4% were taking an immunosuppressant. An equal number of lesions in controls were matched to 148 lesions in males taking beta-blockers, 37 lesions in males taking NSAIDs, and 46 lesions in males taking immunosuppressants. Matching was based on age, PSA, and PI-RADS score. In the matched cohort, neither beta-blockers, NSAIDs, nor immunosuppressants altered clinically significant prostate cancer (csPCa) identification on MRI (OR 1.11, CI 95% 0.6, 1.9; OR 0.70, CI 95% 0.32, 1.66; OR 1.73, CI 95% 0.59, 5.35, respectively).</p><p><strong>Conclusion: </strong>This pilot study shows no difference in csPCa detection rates in patients using anti-inflammatories or drugs that alter prostate blood flow.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"294-300"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrograde intrarenal surgery combined with flexible vacuum-assisted ureteral access sheath versus traditional ureteral access sheath for 1-2 cm lower calyceal renal stones: a prospective, randomized controlled study.","authors":"Yi-Qing Liu, Yue Li, Ji-Dong Guo, Meng-Jun Dai, Qing-Lai Tang, Xing-Zhu Zhou, Rong-Zhen Tao","doi":"10.62347/KMAX4493","DOIUrl":"10.62347/KMAX4493","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of retrograde intrarenal surgery (RIRS) combined with a flexible vacuum-assisted ureteral access sheath (FV-UAS) in patients with 1-2 cm lower calyceal renal stones.</p><p><strong>Patients and methods: </strong>In total, 203 patients with calyceal stones were prospectively randomized into two groups (Clinical trial registration number: ChiCTR2200056402). Of them, 101 patients were assigned to the FV-UAS group and 102 to the traditional UAS group (control). The primary outcome was the stone-free rate (SFR) on postoperative day 1 and in the 4th week. Secondary outcomes included operative time, length of postoperative hospital stay, hospitalization costs, and procedure-related complications.</p><p><strong>Results: </strong>No significant differences were noted in baseline demographics and preoperative clinical characteristics between the two groups (all <i>P</i> > 0.05). Postoperative data indicated that the SFRs on both postoperative day 1 and week 4 were significantly higher in the FV-UAS group than in the traditional UAS group (86.1% vs. 70.6%, <i>P</i> = 0.007; 92.1% vs. 82.4%, <i>P</i> = 0.038, respectively). Hospitalization costs were also lower in the FV-UAS group than in the traditional UAS group ($2524.1 vs. $2635.4, <i>P</i> < 0.001). Furthermore, the incidence rates of postoperative fever, perirenal hematoma, and urosepsis were significantly lower in the FV-UAS group than in the traditional UAS group (fever: 2.0% vs. 8.8%, <i>P</i> = 0.031; hematoma: 0.0% vs. 4.9%, <i>P</i> = 0.024; urosepsis: 1.0% vs. 7.8%, <i>P</i> = 0.018).</p><p><strong>Conclusions: </strong>Our findings suggest that the combination of FV-UAS and RIRS offers a promising treatment approach for 1-2 cm lower calyceal renal stones. This method results in higher SFRs, lower complication rates, and reduced hospitalization costs, making it a valuable technique for clinical adoption.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"256-264"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with time to prostate cancer treatment initiation during the COVID-19 pandemic.","authors":"Ismail Ajjawi, Shayan Smani, Keervani Kandala, Nishan Sohoni, Ryan Sutherland, Samuel L Washington, Isaac Y Kim, Michael S Leapman","doi":"10.62347/BINH7737","DOIUrl":"10.62347/BINH7737","url":null,"abstract":"<p><p>Time from cancer diagnosis to treatment initiation (TTI) can influence clinical outcomes and is a measure of care quality. This study aimed to evaluate the associations between clinical, sociodemographic, and facility-level factors with treatment delays among patients with prostate cancer during the COVID-19 pandemic. We conducted a retrospective analysis of the National Cancer Database (NCDB) for prostate cancer cases diagnosed in 2020 and 2021. We assessed the associations between clinical factors, sociodemographic variables (age, race, ethnicity, sex, income, education, insurance), facility-related factors (facility type, geographic region), and TTI. Multivariable logistic regression was used to identify factors associated with prolonged TTI, defined as the top decile of days to treatment. We identified 160,863 patients, with a median TTI of 71 days (IQR: 43-107). The 90th percentile for TTI was 154 days. Compared to White race, Black (OR 1.39, 95% CI 1.33-1.45), Asian (OR 1.28, 95% CI 1.08-1.52), and Hispanic (OR 1.31, 95% CI 1.21-1.41) patients had significantly longer TTI. Treatment at academic (OR 1.84, 95% CI 1.70-2.00), network (OR 1.37, 95% CI 1.25-1.49), and comprehensive facilities (OR 1.16, 95% CI 1.07-1.26) was associated with longer TTI compared to community facilities. Lastly, private insurance was associated with shorter delays compared to uninsured individuals (OR 0.75, 95% CI 0.71-0.81). Sociodemographic disparities, including race, insurance status, and treatment facility, were associated with longer TTI among prostate cancer patients during the COVID-19 pandemic. These findings can guide efforts to improve timeliness of cancer care.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"306-315"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculous spondylodiscitis with ureteral involvement: a rare case report.","authors":"Nazanin Sadraei, Ali Hekmatnia, Mehdi Salehipour, Farzaneh Hekmatnia, Andrew Parviz Zarei, Shamim Shafieyoon, Farshad Riahi","doi":"10.62347/QURJ3771","DOIUrl":"10.62347/QURJ3771","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis spondylitis, also known as Pott's disease, is a form of osteomyelitis that primarily affects the vertebral bodies and can lead to severe complications such as paravertebral abscesses, kyphosis, and degenerative spinal changes. Although it typically involves the skeletal system, contiguous spread to adjacent organs, such as the genitourinary tract, is rare.</p><p><strong>Methods: </strong>We report the case of a 64-year-old male with chronic back pain who underwent a renal protocol abdominopelvic CT scan following ultrasound findings of right kidney stasis.</p><p><strong>Results: </strong>The CT revealed obstructive uropathy with a dilated and tortuous ureter, a 27×30 mm intraluminal lesion, intraluminal gas, and periureteric fibrosis. Fusion of the L3-L5 vertebrae with gibbous deformity and degenerative changes suggested tuberculous spondylodiscitis with extension to the ureter. Urinalysis was positive for acid-fast bacilli, confirming genitourinary tuberculosis. The patient underwent right ureteronephrectomy due to pyonephrosis and extensive adhesions precluding ureteral reconstruction.</p><p><strong>Conclusion: </strong>This case highlights a rare but serious complication of spinal tuberculosis involving direct spread to the ureter. Timely diagnosis using imaging and microbiological testing, followed by appropriate surgical intervention, is critical to prevent long-term morbidity.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"301-305"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of temsirolimus versus pazopanib in the treatment of advanced renal cell carcinoma: a meta-analysis.","authors":"Yanni Liu, Cuixue Jiang, Guoyang Zhang, Xiuxia Wang, Ruke Sha, Mingyue Liu, Junyi Ma, Zhaohan Sun, Shuo Shen, Yujie Qiu, Shengdong Zhu, Guangbin Sun, Sen Xu, Meiyan Song","doi":"10.62347/XJDW3310","DOIUrl":"10.62347/XJDW3310","url":null,"abstract":"<p><strong>Purpose: </strong>Temsirolimus and pazopanib serve as first-line therapies for renal cell carcinoma (RCC). This meta-analysis was performed to assess and compare their efficacy, optimal treatment targets, and associated toxicities.</p><p><strong>Methods: </strong>We searched the PubMed, CNKI, Wanfang, and VIP databases for relevant literature published from 2003 to 2023. Studies were selected based on specific exclusion criteria, and eligible articles were subjected to data extraction for subsequent subgroup analysis.</p><p><strong>Results: </strong>Fourteen studies of moderate to high quality were included. In the low-risk group, the mortality rate was significantly lower in the temsirolimus group at 0.23 (95% Cl, 0.15-0.31) compared to 0.44 (95% Cl, 0.40-0.47) in the pazopanib group. In the high-risk group, the mortality rate was 0.73 (95% Cl, 0.69-0.76) for temsirolimus and 0.67 (95% Cl, 0.64-0.71) for pazopanib.</p><p><strong>Conclusion: </strong>Temsirolimus demonstrated greater efficacy in the low-risk group, while pazopanib was superior in the high-risk group for the treatment of RCC. Consideration of both efficacy and toxicity is crucial to guide drug selection for patients. TRN: CRD42024578497 (Registration date: 2024/08/21).</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"272-283"},"PeriodicalIF":1.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of continuous nursing based on the Omaha System in patients with double-J stents after upper urinary tract stones surgery: a prospective study.","authors":"Hui Huang, Ping Liang, Ting-Ting Shao, Li Fang, Fang-Fang Zhang, Rong-Zhen Tao","doi":"10.62347/XBFV3220","DOIUrl":"10.62347/XBFV3220","url":null,"abstract":"<p><strong>Objective: </strong>To explore the efficacy and safety of continuous nursing based on the Omaha System in patients with double-J stents after upper urinary tract stones surgery.</p><p><strong>Patients and methods: </strong>A total of 171 patients who underwent upper urinary tract stones surgery in our department from July 2022 to December 2023 were selected. According to the envelope randomization method, patients were divided into a control group (85 cases) and a study group (86 cases). In the control group, we carried out discharge education upon discharge, distributed health education manuals, explained the nursing, diet, daily exercise, and other precautions for indwelling double-J stents outside the hospital. On the basis of the control group, the Omaha System will be used to evaluate nursing issues, including the four aspects with the highest post discharge nursing needs: physiological, psychological, environmental, and health-related behaviors. Then, problem oriented continuous nursing.</p><p><strong>Results: </strong>After nursing intervention, the cognitive score, behavioral score, and condition score of the two groups were separately higher than pre-nursing, and the scores in the study group were all significantly higher than those in the control group (P < 0.05). With respect to the secondary important variables, the overall incidence of complications in the study group was significantly lower than that in the control group (P < 0.05).</p><p><strong>Conclusions: </strong>The application of continuous nursing based on the Omaha System in patients with double-J stents after upper urinary tract stones surgery can improve nursing outcomes, reduce the incidence of complications, and enhance self-care capabilities.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 3","pages":"233-240"},"PeriodicalIF":1.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in men with benign prostatic hyperplasia and overactive bladder in a prospective randomized controlled trial.","authors":"Yu-Rui Tang, Qing Wei, He-Wei Xu, Jie Xu, Yun-Peng Li","doi":"10.62347/TMQG2381","DOIUrl":"10.62347/TMQG2381","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the therapeutic efficacy and safety profile of pelvic floor magnetic stimulation (PFMS) in combination with mirabegron in male patients diagnosed with benign prostatic hyperplasia (BPH) and overactive bladder (OAB).</p><p><strong>Patients and methods: </strong>Eighty-six patients were prospectively randomized into two cohorts. The control group received oral mirabegron (50 mg daily), whereas the experimental group underwent combined PFMS and mirabegron therapy. Primary endpoints included variations in urinary frequency and urgency intensity, measured through a 3-day voiding diary. Secondary endpoints included changes in the International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q) Health-Related Quality of Life (HRQol) index, and symptom burden, assessed at weeks 6 and 12.</p><p><strong>Results: </strong>Among the participants, 42 received the combination therapy and 44 received mirabegron monotherapy. At both time points, the combination group demonstrated significantly reduced lower urinary tract symptoms (LUTS) - including urgency, frequency, and incontinence - relative to the monotherapy group (<i>P</i> < 0.05). Moreover, OAB-q HRQol scores were consistently higher in the combination group (<i>P</i> < 0.05). Significant improvements were also observed in the IPSS, OAB-q symptom bother index, and Overactive Bladder Symptom Score (OABSS) within the combination cohort (<i>P</i> < 0.05). The incidence of drug-associated adverse events did not differ significantly between groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>PFMS combined with mirabegron markedly alleviated BPH and OAB symptoms and improved patient-reported quality of life, without increasing the risk of adverse events compared to mirabegron monotherapy.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 3","pages":"215-224"},"PeriodicalIF":1.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of tracking extended nursing on patients with urinary tract stones after holmium laser lithotripsy: a prospective study.","authors":"Yu-Yun Wu, Rui Zhang, Mei Li, Ying-Ying Guo, Rong-Zhen Tao, Shuang Zhou","doi":"10.62347/RIJM8139","DOIUrl":"10.62347/RIJM8139","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the efficacy and safety of tracking extended nursing (TEN) on patients with urinary tract stones after holmium laser lithotripsy (HLL).</p><p><strong>Patients and methods: </strong>A total of 232 patients with urinary tract stones after HLL were prospectively randomized into 2 groups. One hundred and sixteen patients in the study group accepted TEN mode and 116 patients serving as control accepted only traditional nursing mode. The Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) scores, measured at different time points, were considered the primary outcomes for evaluating patients' psychological state. The secondary end points were Quality of life (QOL) scores and complications between the two groups.</p><p><strong>Results: </strong>After the TEN mode was applied to the study group, the HAMD and HAMA scores were significantly lower than those in the control group at the second and fourth week (P<0.05). With regard to the secondary variables, the QOL scores in the study group was significantly higher than that in the control group at the second and fourth week (P<0.05). In addition, the overall incidence of complications was significantly lower in the study group than in the control group (P<0.05). No serious complications were reported in either group.</p><p><strong>Conclusions: </strong>The TEN mode improves psychological well-being and Qol in urinary tract stone patients undergoing HLL, accelerates recovery, reduces complications, and enhances self-care.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 3","pages":"241-248"},"PeriodicalIF":1.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}